William G. Macdonald
Murdoch, WA, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 26, 2026
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: November 29, 2024
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.
Journal: The Lancet. Oncology
Published: July 09, 2024
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 14, 2024
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Journal: The Lancet. Oncology
Published: August 30, 2023
Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu-octreotate peptide radionuclide therapy.
Journal: Cancer
Published: October 13, 2021
Technetium-99 m-sestamibi single-photon emission computerised tomography (CT)/CT in the prediction of malignant versus benign small renal masses.
Journal: BJU international
Published: September 24, 2021
Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma.
Journal: British journal of haematology
Published: August 09, 2021
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Journal: Lancet (London, England)
Published: December 22, 2020
The effect of Vitamin-K1 and Colchicine on Vascular Calcification Activity in subjects with Diabetes Mellitus (ViKCoVaC): A double-blind 2x2 factorial randomized controlled trial.
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: August 23, 2020
Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours.
Journal: Oncotarget
Published: May 09, 2020
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care.
Journal: Journal of clinical medicine
Published: July 31, 2019
Last Updated: 09/26/2026